Update on Current Research and Rollout of PrEP for Women in the US



Featuring

- Dr. Sharon Hillier, University of Pittsburgh Medicine, MTN
- Dr. Sally Hodder, Rutgers NJ Medical School, HPTN
- Dr. Dawn Smith, US Centers for Disease Control

This is the first in a series of webinars coordinated by partners in the US Women and PrEP Working Group – learn more at www.prepwatch.org/#women.



SísterLove, Inc.



US Women and PrEP Working Group

- Coalition of more than 50 women from leading AIDS and women's health organizations—formed in March 2012—to build a common understanding of what PrEP as a new HIV prevention tool could mean for women in the United States.
- □ Focus on:
 - How will PrEP be used for HIV prevention by women in the US?
 - What data are needed regarding PrEP's acceptability and effectiveness among those women?
 - How will PrEP be promoted, made accessible and financed for use by US women?
- Recent work includes a statement calling for a coordinated, timely and adequately funded US government response to PrEP for women that involves the full participation and leadership of individuals and communities most in need of effective, comprehensive HIV prevention.
- □ For more visit <u>www.prepwatch.org/#women</u> and if interested in joining the group please send your request to <u>avac@avac.org</u>.

PrEP Study Results				
Study	Population	Ν	Treatment(s)	Results
iPrEx Brazil, Ecuador, Peru, South Africa, Thailand, US	Gay men, other MSM, transgender women	2499	Daily oral Truvada	44% efficacy
TDF2 Study Botswana	Men and women	1200	Daily oral Truvada	62% efficacy
Partners PrEP Study Kenya, Uganda	Serodiscordant couples	4758	Daily oral Tenofovir Daily oral Truvada	67% efficacy 75% efficacy
Bangkok Tenofovir Study Thailand	IDUs	2400	Daily oral Tenofovir	49% efficacy
FEM-PrEP Kenya, South Africa, Tanzania	Women	1950	Daily oral Truvada	No effect
VOICE South Africa, Uganda, Zimbabwe	Women	5029	Daily oral Tenofovir Daily oral Truvada Daily vaginal TFV gel	No effect

Ongoing and Planned PrEP Demonstration Projects and Trials in Women, August 2013				
Trial/project	Location	Population	Sponsor/funder	Status
Partners Demo Project	Kenya, Uganda	Serodiscordant couples	Scientists from Kenya, Uganda and the US; funded by NIMH/NIH, USAID and BMGF	Ongoing; results expected in 2016.
LVCT and SWOP	Kenya	Young women, female sex workers, MSM	_	In development
Nigerian National Agency for the Control of AIDS	Nigeria	Serodiscordant couples	National partners, O'Neill Institute, LSHTM,	In development
Wits Reproductive Health and HIV Institute	South Africa	Female sex workers	Imperial College, UNAIDS and WHO; funded by BMGF	In development
Durbar (DMSC) and Ashodaya Samithi	India	Female and transgender sex workers		In development
Choices For Adolescent Methods Of Prevention In South Africa (CHAMPS)	South Africa	Heterosexual men and women	NIAID	Ongoing; results expected June 2015.
Victorian PrEP Demo Project	Australia	At risk-population	Victorian AIDS Council/Gay Men's Health; funded by Victorian Government	In development
CDC Foundation Demo Project	US	MSM and heterosexual women	Funding pending	In development
CDC 494 (TDF2 Follow-Up)	Botswana	Heterosexual men and women	Botswana MOH, CDC, Gilead	Ongoing; results expected in Nov. 2013.
HPTN 069/ACTG 5305 (NEXT-PrEP)	US	MSM and at-risk women	ACTG, HPTN, NIAID	Ongoing; results expected Dec. 2014.
For a complete list of ongoing and planned PrEP demonstration projects and trials in all populations see <u>www.avac.org/prepdemo</u>				

Discussion

- Unmute your line by pressing *7 and ask it on the line (remute your line by pressing *6)
- Enter it into the chat box in ReadyTalk
- Email your question to <u>avac@avac.org</u>
- Tweet @hivpxresearch

Webinar recording will be available at <u>www.avac.org/meetingreports</u> and <u>www.prepwatch.org</u>

Visit <u>www.prepwatch.org/#women</u> for more on the working group and info on upcoming webinars

Join us for next month's webinar

PrEP-ception: sero-discordant couples using PrEP to reduce HIV transmission risk while achieving pregnancy

Monday, October 28, 2013

11:00 AM - 12:30 PM EDT

- Introduction: Overview of PrEP and the Role of the Working Group
 - Dazon Dixon Diallo, MPH, Founder and President, SisterLove, Inc.
- Defining the Need for Safer Conception Options: The Role of "PrEP-ception"
 - Shannon Weber, MSW, Director, Perinatal HIV Hotline, Bay Area Perinatal AIDS Center
- A Framework for the Integration of PrEP
 - Erika Arron, CRN, Drexel University College of Medicine, Division of Infectious Diseases and HIV Medicine
- One Mom's Story
 - Рорру
- Questions and Discussion
 - Dazon Dixon Diallo, Moderator

Register at www.prepwatch.org/uswomenwebinars



VOICE Results: Questions and Implications

Sharon Hillier Microbicide Trials Network

Ready, Set, PrEP: Update on Current Research and Rollout of PrEP for Women in the US (webinar) September 16, 2013



Overview

VOICE results recap

- Questions still to be answered
- What does VOICE say about women and PrEP?
- Summary and conclusions









Which is effective? Is each safe? Which will women use?





Women enrolled between Sept 2009 – June 2011

Screened 12,320 women to enroll 5,029



UGANDA: 322 participants

Makerere Univ./JHU, Kampala: 1 site

ZIMBABWE: 630 participants

- UZ-UCSF, Harare: 1 site
- UZ-UCSF, Chitungwiza: 2 sites

SOUTH AFRICA: 4,077 participants

Durban

- Medical Research Council: 7 sites
- CAPRISA eThekwini: 1 site

<u>Johannesburg</u>


- WRHI: 1 site
- PHRU Soweto: 1 site

Klerksdorp

Aurum Institute: 1 site

Half of the women were under 25, 80% were unmarried

How was the study done?








What VOICE found

- Daily approach gel or tablet was not right for the population of women in VOICE
 - No product was effective
 - Most participants did not use the products
- Younger (under 25), unmarried women were least likely to use the products and the most likely to acquire HIV
- HIV incidence was 5.7% twice what we estimated and nearly 10% at some South African sites
- Study retention was very high (91%)
- No safety concerns with the products





HIV seroconversion endpoints*



* Includes data through 12/6/2012

No significant difference in efficacy

	Tenofovir Tablet*	Oral Placebo*	Truvada Tablet	Oral Placebo	Tenofovir Gel	Gel Placebo
Person-yrs	823	837	1285	1306	1026	1030
No. of HIV infections	52	35	61	60	61	70
HIV incidence per 100 p-y	<mark>6.3</mark> [4.7, 8.3]	4.2 [2.9, 5.8]	4.7 [3.6, 6.1]	4.6 [3.5, 5.9]	5.9 [4.5, 7.6]	6.8 [5.3, 8.6]

*Censored on date when sites were informed to take women off of tenofovir and placebo tenofovir tablets





Results for product adherence

Analyzed blood samples from 773 participants (including 185 women who acquired HIV) for presence of drug

- □ Adherence to product use was low across all groups
 - Drug detected in less than 1/3 of samples from women in Truvada and oral tenofovir groups
 - Drug detected in less than 1/4 of samples from women in tenofovir gel group
 - More than 50% of women never had <u>any</u> drug detected
- Adherence estimated to be 90% based on what participants reported and counts of unused applicators and leftover pills





Adherence from 3 Different Measures

	Truvada Tablet	Tenofovir Tablet	Tenofovir Gel
Returned Pill or Applicator Counts	92%	87%	86%
Self Report	91%	90%	90%
Drug Detected in Blood	29%	28%	23%
Percentage of women with <u>no drug</u> detected in <u>any</u> sample	50%	58%	55%





Young, unmarried women

Compared to older, married women in VOICE, those under age 25 and not married were:

Least likely to use study product

 Drug was detected in 21% of young, unmarried women vs. 54% of the older, married women in the Truvada group

Most likely to acquire HIV

- HIV incidence was 8.8% vs.0.8%
- Overall HIV incidence in study was 5.7%





Social Science/ Behavioral Research

- Social/behavioral scientists engaged at every step
- Oversaw modification of counseling approach during VOICE
 included client-centered motivational counseling
- Introduced community-centered, ethnographic study: VOICE C
 - Conducted at the WRHI trial site in Johannesburg
 - Looked at factors and beliefs within women's communities, social groups and households that may have influenced ability and willingness to use products
 - Involved VOICE participants, male partners, CAB members and community stakeholders





Contemporal Content of Advantages of Questions!?!

- Why did women join VOICE and attend all study visits but not use the products?
 - Did they participate for other reasons, e.g., health care services and HIV testing the study provides?
 - Why did they go to great lengths to hide non-use?
 - They live where incidence is very high don't they see themselves at risk?
 - Why didn't they or couldn't they use the products?
 - Was there stigma with ARV-based products?
 - Even after being told that other trials found regular use effective, they still didn't use the products – why not?
 - Will they use other prevention products? Especially ones that may be easier to use?



Seeking Answers: VOICE D

- Behavioral sub-study launched after VOICE still ongoing
- Involves former VOICE participants at 5 sites in Uganda, Zimbabwe and South Africa
- Aims to better understand women's actual and reported use of study products and sexual behavior during VOICE
- □ Part 1 (completed) 88 women after they exited VOICE
- In-depth interviews focused on perceptions and understanding of risk behaviors, e.g., anal sex
- □ Part 2 108 -144 women who were on active product
- Results of their own blood tests (drug levels) to be used as ice-breaker for in-depth interviews and focus group discussions to get to reasons for non-use





Answering other questions







- More information about who used products
 - Blood samples were tested for drug in only 15% of the participants
 - Now testing *every* sample collected from *all* 5,029 women – 160,000 plasma samples alone
- Effects of oral products on bone health
 - VOICE-B results awaiting additional data on drug levels and product use
- Frequency of drug resistance
- Effects of tenofovir gel on HSV-2 acquisition



Truvada and women?

- Effective in Partners PrEP
 - Women were older (mean age 36)
 - All in committed relationship with a partner they knew was HIV-positive; both partners aware of HIV risk
- Effective in TDF2
 - Relatively small study
 - Effect size in women (49.4% in sub-analysis) not statistically significant-- (wide CI: -0.217% to 80.8%)
- Not effective in FEM-PrEP
 - Similar population to VOICE 59% under age 25
 - 70% perceived themselves at little or no risk of HIV
- Not effective in VOICE





Truvada and women?

	Avg # women per arm	Avg # woman yrs follow-up per arm	Women on active product (Truvada)	Women yrs follow-up on active product
Partners PrEP	595	920	873	1,271
TDF2	278	351		.,
FEM-PrEP	1,060	703		
VOICE	1,006	1,126	2,066	1,829







A few take-home messages

- Even the most effective product will do no good if it's not used (or not used correctly)
 - The women who need safe and effective HIV prevention methods must also be willing and able to use them and they must actually use them
- Low adherence in a clinical trial can provide important clues about potential "real world" use
 - Is there stigma with using an ARV product for prevention?
 - Is daily use asking too much?





Summary and Key Points

- Results of VOICE are clear: daily use (gel or tablet) was not right approach for the women in VOICE
- Young, unmarried women used product the least and acquired HIV the most



- □ Hope to understand *why* women didn't use products
- VOICE is consistent with FEM-PrEP results for Truvada – together, send very strong message

Need products women <u>will</u> use



- Exploring long-acting methods: ASPIRE and The Ring Study of monthly dapivirine ring
- Next generation:
 - Products that also provide contraception





More to come....

- Primary results expected to be published soon
- □ VOICE C results to be reported before end of 2013
- VOICE D expected to be completed by end of 2013 and report results mid 2014
- □ VOICE B results (bone health) available in 2014
- Complete analysis of all drug plasma levels in VOICE by ????





Acknowledgements



Women need safe and effective HIV prevention products!

We are grateful to the women who participated in VOICE, to the community and family members who supported their participation, and to everyone who continues to support HIV prevention research so that someday we may all live in an AIDS-free world.

MTN is funded by NIAID (AI068633), NICHD and NIMH, all of the U.S. National Institutes of Health







PrEP Research Agenda in the HPTN

Sally L. Hodder, MD

SEPTEMBER 16, 2013





National Institute

of Mental Health



U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIDA NATIONAL INSTITUTE ON DRUG ABUSE





HIV Incidence Among US Women HPTN 064: The Women's HIV SeroIncidence Study (ISIS)





National Institute

of Mental Health



U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NATIONAL INSTITUTE ON DRUG ABUSE



ISIS Objectives

- Accurately estimate new HIV incidence in a group of women at risk for HIV in the US
- Evaluate new lab methods for identification of new HIV infections
- Describe factors in participants lives that impacted HIV risks
 - For example, partner risks, alcohol/ use, financial factors, condom use





ISIS Inclusion Criteria

- Self identifies as a woman ages 18-44 years
- Residence in area with relatively high rates of HIV prevalence and poverty
- Unprotected sex with a man during the previous 6 months
- AND at least one additional risk factor





Study Sites

Bronx and Harlem, NY North and South Newark, NJ Baltimore, MD Washington, DC Durham and Raleigh, NC Decatur and Atlanta, GA

10 distinct communities within 6 geographic locations Qualitative data collected in four communities





ISIS Cohort Baseline Characteristics n=2,099

		Number	Percentage ^a
Median Age		29	[23 – 38]
Race	Black	1851	88.2
Hispanic Ethnicity		245	12
Education	< high school graduation	777	37.0
Marital Status	Single/Divorced/Widowed	1258	59.9
	Married/Living with partner	638	30.4
Annual Household	<\$10,000	932	44.4
Income	\$10,000 - \$20,000	225	10.7
	>\$20,000	197	9.4
	Unknown	745	35.5
Food Insecurity	Concerns for self and/or family	971	46

^aNumber and percentage shown for all variables except age which shows median, interquartile range.





Reported Characteristics at Baseline (all risk factors within 6 months)

FACTOR	%
<u>> Monthly binge drinking > 4 drinks on one occasion</u>	39
Intravenous drug use	4
Exchange sex for commodities	37
Unknown HIV status of last vaginal sex partner	41
Anal sex	40
Condom at last vaginal sex	18
Condom at last anal sex	18



HIV Prevalence and Incidence in Context

- Thirty-two women (1.5%) entered the study unaware of their HIV infection, suggesting that testing programs must improve coverage
- Annual incidence of 0.32% is more than 6 times the CDC estimated national incidence for similarly aged black women






Univariate Analysis of Potential Factors Associated with HIV Infection

Participant Risk Factors	Prevalent HIV (n=30)	Incident HIV (n=8)
Substance Use ^a	2.52 (1.22, 5.21) ^b	0.57 (0.06, 3.18)
Age (27-33 vs. 18-26)	5.83 (1.22, 27.96) ^b	0.84 (0.08, 5.89)
Age (34+ vs. 18-26)	11.54 (2.71 <i>,</i> 49.05) ^b	0.57 (0.05 <i>,</i> 3.94)
HIV Diagnosis of	8.19 (2.64, 25.42) ^b	0.0 (0.0, 47.90)
partner		




HIV Combination Prevention





HIV Combination Prevention



US Women are Being Prescribed PrEP

- Between January 2011 and March 2013, pharmacy data from ~55% US pharmacies assessed for PrEP prescriptions
- Total of 1,774 subjects were identified as starting TVD for PrEP.
 - 47.7% women



HIV PREVENTION TRIALS NETWORK

HPTN PrEP Agenda

- Evaluate the efficacy of an ARV regimen containing new oral drugs (such as maraviroc (MVC) for PrEP
- Develop new agents and new formulations for PrEP including long lasting injectables
- Develop pharmacostatistical models to define the role of new agents for PrEP

HPTN Pre- Exposure Prophylaxis (PrEP) Studies



HPTN 067 The ADAPT Study: <u>Alternative Dosing to Augment PrEP</u> pill-<u>Taking</u>



HIV Prevention Trials Network





Main Study Questions

- How does taking oral Truvada[®] tablets intermittently compare to taking the tablets daily? Will participants in the intermittent groups:
 - have the same coverage of sex events,
 - need fewer tablets for coverage, and
 - report fewer side effects compared to participants who take their tablets daily?



Study Groups

Truvada taken:


1. Daily

HIV Prevention Trials Network

- 2. Event-driven (before and after sex)
- 3. Time-driven (2 times a week and a booster after sex)

No more than

- 2 tablets in a 24-hour period
- 7 tablets in a week.



HIV PREVENTION TRIALS NETWORK



HPTN 069/ACTG 5305 NEXT-PREP: <u>Novel Exploration of</u> Therapeutics for <u>PREP</u>



HIV PREVENTION TRIALS NETWORK



HPTN 069 Study Groups

- There are 3 active drugs:
 - maraviroc (MVC)

HIV Prevention Trials Network

- emtricitabine (FTC)
- tenofovir (TDF)
- Study Regimens (3 pills/arm):
 - maraviroc + FTC placebo + TDF placebo
 - maraviroc + emtricitabine + TDF placebo
 - maraviroc + tenofovir + FTC placebo
 - tenofovir + emtricitabine + MVC placebo





HPTN 069 Endpoints

Primary Endpoint:


• Grade <u>></u>3 toxicities; time to study treatment discontinuation

Secondary Endpoints:

- Assess changes in bone mineral density
- Evaluate drug concentrations of in plasma, peripheral blood mononuclear cells (PBMC), rectal tissue and fluid, and cervical tissue and cervicovaginal fluid, in a subset of participants
- Assess adherence as measured by an electronic drug monitoring device (EDM)
- Assess and characterize sexual behavior over time as measured by computer-assisted selfinterview (CASI).
- Evaluate the association of drug concentrations with other adherence measures

Exploratory Objective

• Determine whether oral PrEP is associated with suppression of HIV replication in colorectal and cervical explants (*ex vivo* HIV challenge, Tissue Subset).



HPTN 073: PrEP Adherence and Uptake Among BMSM in Three US Cities





HPTN 073 Study Design

- Demonstration project
- Once daily oral emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg (FTC/TDF)
- Client-centered care coordination (C4)



HIV PREVENTION TRIALS NETWORK

Main Study Questions

- How willing BMSM are to take PrEP
- How consistently the men who do decide to take PrEP, take it as prescribed
- How the men evaluate the experience of using PrEP, and
- Is it acceptable for local health care facilities to administer client-centered care coordination (C4) along with PrEP to BMSM



HIV PREVENTION TRIALS NETWORK

HPTN 076: Injectable Pre-Exposure Prophylaxis (PrEP)





HPTN 076 Main Study Questions

- Is injectable rilpivirine PrEP safe for women?
- Will women find injectable PrEP acceptable for use?
- Is injectable PrEP tolerable for women?



Study in Development

- Total of 132 participants participants at 4 sites
 - 48 at each international site
 - 18 at each US site
- Injectable PrEP vs injectable placebo

HIV Prevention Trials Network

Conclusions

- Existing data suggest that US women are at risk and are actively being prescribed antiretroviral therapy for prophylaxis
- HPTN research agenda assesses novel PrEP agents and administration strategies
- Data to be generated from the HPTN addresses the need for increased PrEP options



THANK YOU

Wafaa EI-Sadr, MD, MPH Jonathan Lucas, MPH Niru Sista, PhD Sponsors HPTN Investigators and Study Staff Participants of past and current HPTN studies









U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NITIONAL INSTITUTE ON DRUG ABUSE

PrEP Update: The science, new tools, and next steps

Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC US Women & PrEP WG Webinar 16 September 2013



"The findings and conclusions in this presentation have not been formally disseminated by the CDC and should not be construed to represent any agency determination or policy"




PrEP Efficacy by Adherence

Intervention	mITT	Self-report, dia	Drug detected			
Male condom (HET)	-	80% (always vs never)	<10% (sometimes vs never)	-		
PrEP – TDF/FTC (iPrEx, MSM)	44%	73% (>90% self-report+pill count)	50% (>50% self report+ pill count)	92%		
PrEP — TDF/FTC (Partners PrEP, HET)	75%	100% (>80% pill count)	-	90%		
PrEP — TDF (BTS)	49% 56% (>71% diary)		-	70%		


Sources: Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev.* 2002(1):CD003255. Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *NEJM.* 2010;363(27):2587-2599. Baeten JM et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. *NEJM.* 2012;367(5):399-410. Choopanya K et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand. *Lancet* 2013;381(9883):2083-2090.

Relative risk reduction in acquiring HIV infection (compared with placebo) based on plasma TFV concentrations (Partners PrEP)



TVF level

Resistance, ART, and PrEP




Implementation Science

- Adoption
- Diffusion (passive)
- Implementation (active)
- Institutionalization (sustainability)

Uptake of ZDV for perinatal prevention

(in 18 states with HIV surveillance)




ACTG 076 results and PHS guidelines published

PrEP Cascade

Patients

Providers



Evidence of PrEP Use HIV Care Providers, mid-2011

- 78% had read Interim Guidance for MSM
- 43% had patients who requested PrEP
- 19% had prescribed PrEP, of those
 - 78% for MSM 31% for MSW 28% for WSM
 - 83% prescribed TDF/FTC
 - 92% documented initial HIV-negative status
 - 25% did not test for acute HIV infection-if symptomatic
 - 17% did not confirm ongoing risk behaviors

Estimating PrEP Uptake

- 3,000+ patients in US PrEP post-approval studies 2013-2014
- Gilead analysis:
 - Retail prescriptions for ~ 55% of US pharmacies, claims data
 - PrEP prescribers in ~700 US cities, 49 states
 - 31% family practice and internal medicine
 - 17% non-physician prescribers (NP and PA)
 - 14% emergency medicine
 - 12% infectious disease
 - 37% also prescribed Truvada for HIV treatment
 - Prescriptions increasing 2011-2013
 - 13.6% were for persons under age 25 years
 - 47.7% were for women
 - In 2013, anticipated as many as 2545 PrEP prescriptions

Tools for implementation of PrEP in clinical practice

- PrEP Guidelines
 - Interim guidance
 - PHS guidelines
 - Local protocols
- Risk screening tools (for MSM, IDU, HRH, and HDC)
- Local prevalence data
 - Health department reports
 - www.AIDSvue.org
- Brief risk counseling protocols
- Billing codes for PrEP-related care

PrEP Patient Assistance Program

Gilead Sciences, Inc.

Medication Assistance Program

Statement of Medical Necessity 2

Statement of Medical Necessity for Financially Needy Applicants. To the best of my knowledge, this applicant has no coverage (including Medicaid or other public programs) for TRUVADA. I certify that the medication(s) listed above are medically indicated for this applicant and that I will be supervising the applicant's treatment. I certify that I am prescribing TRUVADA for PrEP as part of a risk reduction strategy for HIV prevention for this applicant. I certify that the applicant has been tested for HIV infection and found to be HIV negative, and regular HIV testing will be conducted as part of the applicant's care plan. As part of my applicant's eligibility, I agree to periodically verify continued use of Gilead medication and resubmit current prescriptions.

SIGN HERE

Prescriber Signature:	Prescr	lber	Sig	na	tur	e:
-----------------------	--------	------	-----	----	-----	----

Date:

When complete, FAX application and documentation to: 1-855-330-5478

Applications are considered complete only if they include all of the following:

- Front and Back Pages of Enrollment Form
- Applicant as well as Prescriber Signation
- Documentation of Income Sources an


Copy of Prescription

natures and Dates s and Residency	P.O. Box 13185	ance Program									
			MM	DD	****	Gende	n -	Resid	les in	U.S/U.S.	territories:
Social Security #:		Date of Birth:	/		/	м 🗆	F 🗆	YES		NO [
Primary Contact:	Relationsh	Relationship:			Phone Number:						
Applicant Financial Informatio	'n										
Current Annual Household Incor Please include current documental						1 2	3	4	5	6	
Applicant is insured (Please f	ill out all the applicable insur	ance information b	elow. Atta	ach cop	y (front a	nd back) of ap	plicant	: insu	rance o	card.)
Applicant is uninsured (No here)	ealth insurance through any	public or private p	ayer.) Com	plete *	Addition	al Insu	rance I	nform	atio	n" belo	w.

Next Steps

- With what we know now:
 - Increase awareness and linkage to clinical care for persons who might benefit from PrEP use
 - Increase awareness and training for providers interested in offering PrEP to their patients
 - Increase systematic monitoring of PrEP use and its health impact
- With what we will learn soon:
 - Incorporate lessons learned from OLE and demonstration projects
 - Continue implementation research
 - Continue clinical research

Post-Trial PrEP Studies





Dr. Dawn K. Smith dsmith1@cdc.gov 404.429.0904

"The findings and conclusions in this presentation have not all been formally disseminated by the CDC and should not be construed to represent any agency determination or policy"